BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 35165928)

  • 1. Chidamide with PEL regimen (prednisone, etoposide, lenalidomide) for elderly or frail patients with relapsed/refractory diffuse large B-Cell lymphoma -results of a single center, retrospective cohort in China.
    Wang Y; Xue H; Song W; Xiao S; Jing F; Dong T; Wang L
    Hematol Oncol; 2022 Oct; 40(4):617-625. PubMed ID: 35165928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
    Tian C; Chen Z; Li Y
    J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
    Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
    J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Czuczman MS; Trněný M; Davies A; Rule S; Linton KM; Wagner-Johnston N; Gascoyne RD; Slack GW; Brousset P; Eberhard DA; Hernandez-Ilizaliturri FJ; Salles G; Witzig TE; Zinzani PL; Wright GW; Staudt LM; Yang Y; Williams PM; Lih CJ; Russo J; Thakurta A; Hagner P; Fustier P; Song D; Lewis ID
    Clin Cancer Res; 2017 Aug; 23(15):4127-4137. PubMed ID: 28381416
    [No Abstract]   [Full Text] [Related]  

  • 5. PD-1 blockade combined with ICE regimen in relapsed/refractory diffuse large B-cell lymphoma.
    Ping L; Gao Y; He Y; Bai B; Huang C; Shi L; Wang X; Huang H
    Ann Hematol; 2023 Aug; 102(8):2189-2198. PubMed ID: 37306710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from GELTAMO.
    Martín García-Sancho A; Baile M; Rodríguez G; Dlouhy I; Sancho JM; Jarque I; González-Barca E; Salar A; Espeso M; Grande C; Bergua J; Montes-Moreno S; Redondo A; Enjuanes A; Campo E; López-Guillermo A; Caballero D
    Br J Haematol; 2023 Oct; 203(2):202-211. PubMed ID: 37485564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.
    Hu S; Zou D; Zhou D; Zhang Y; Wang W; Zhang W
    Medicine (Baltimore); 2020 Oct; 99(43):e22788. PubMed ID: 33120793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Programmed cell death-1 inhibitor combined with rituximab in refractory or relapsed diffuse large B-cell lymphoma: a preliminary efficacy and safety analysis].
    Qin Y; Zhao FY; Zhou Y; Jiang SY; Yang S; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Dec; 42(12):1034-1039. PubMed ID: 33342160
    [No Abstract]   [Full Text] [Related]  

  • 12. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
    Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
    Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
    Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
    Palazón-Carrión N; Martín García-Sancho A; Nogales-Fernández E; Jiménez-Cortegana C; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Salar-Silvestre A; Rodríguez-Abreu D; Gálvez-Carvajal L; Labrador J; Guirado-Risueño M; García-Domínguez DJ; Hontecillas-Prieto L; Espejo-García P; Fernández-Román I; Provencio-Pulla M; Sánchez-Beato M; Navarro M; Marylene L; Álvaro-Naranjo T; Casanova-Espinosa M; Sánchez-Margalet V; Rueda-Domínguez A; de la Cruz-Merino L
    Clin Cancer Res; 2022 Sep; 28(17):3658-3668. PubMed ID: 35727601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†.
    Ghesquieres H; Chevrier M; Laadhari M; Chinot O; Choquet S; Moluçon-Chabrot C; Beauchesne P; Gressin R; Morschhauser F; Schmitt A; Gyan E; Hoang-Xuan K; Nicolas-Virelizier E; Cassoux N; Touitou V; Le Garff-Tavernier M; Savignoni A; Turbiez I; Soumelis V; Houillier C; Soussain C
    Ann Oncol; 2019 Apr; 30(4):621-628. PubMed ID: 30698644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zanubrutinib-lenalidomide-rituximab (ZR
    Wang Y; Xu J; Li P; Xu Y; Xue H; Liu P
    Ann Hematol; 2024 Feb; 103(2):499-510. PubMed ID: 37957370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: a multicenter, single-arm, phase II study.
    Chen X; Wang H; Sun X; Su L; Liu F; Zhao K; Xu L; Wu S; Song T
    Ann Transl Med; 2021 Dec; 9(24):1769. PubMed ID: 35071463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carfilzomib combined with rituximab, ifosfamide, carboplatin, and etoposide for relapsed or refractory DLBCL.
    Torka P; Groman A; Wong J; Nichols J; Kader A; Mavis C; Anampa-Guzmán A; Sait SJ; Block A; Przespolewski E; Mohr A; Lund I; McWhite K; Kostrewa J; DeMarco J; Johnson M; Darrall A; Thomas R; Sundaram S; Ghione P; Hutson A; Hernandez-Ilizaliturri FJ
    Blood Adv; 2023 Apr; 7(7):1146-1155. PubMed ID: 36375132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.